ANNAPOLIS, Md., Sept. 13, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax ® next-generation anthrax vaccine program were presented at the 53 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax ® provides dose-dependent protection against lethal anthrax infection.
Dr. Sherry Crowe, Director, Immunology at PharmAthene, discussed the results in an oral presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax ® ) Provides Protection against Lethal Challenge with Bacillus anthracis in New Zealand White Rabbits."
Summary of SparVax ® Findings Reported
The need for newer anthrax vaccines based on modern vaccine technology, which offer the potential for improved safety, convenience and cost-effectiveness, is widely acknowledged. SparVax ® is a next-generation anthrax vaccine based on recombinant protective antigen (rPA), the principal virulence factor of the organism, B. anthracis. It is being developed for pre- and post-exposure protection against anthrax.Previous non-clinical animal studies have demonstrated that immunization with SparVax ® stimulates the production of anti-PA antibodies that provide protection against anthrax infection. The objective of the current study was to provide further confirmation of the immunogenicity and efficacy of SparVax ® (manufactured in the U.S.) and determine the optimal dose range for protection. In the current study, New Zealand White rabbits were administered escalating doses of SparVax ® ranging from 0.003 micrograms to 1.0 micrograms of rPA. Control animals received either no immunization or were administered saline. Following immunization, the animals were challenged with B. anthracis spores (Ames strain). The results demonstrated that SparVax ® was effective in providing protection against lethal inhalation anthrax challenge and resulted in no adverse clinical observations. In the study, immunization with SparVax ® stimulated a dose-dependent antibody response, which correlated with survival. "PharmAthene is pleased to be working in partnership with the Biomedical Advanced Research and Development Authority (BARDA) towards our mutual goal of advancing novel, next-generation anthrax vaccines to address important national security initiatives," said Eric I. Richman, President and Chief Executive Officer. "We look forward to continuing this progress and commencing a Phase 2 clinical trial of SparVax ® later this year." Important Additional Information about the Proposed Merger On August 1, 2013, PharmAthene filed with U.S. Securities and Exchange Commission (the "SEC") a current report on Form 8-K, which includes a copy of a merger agreement and related documents relating to a proposed merger involving Theraclone Sciences, Inc. ("Theraclone") and PharmAthene. On September 9, 2013, PharmAthene filed a registration statement on Form S-4 with the SEC, which contains a preliminary proxy statement/prospectus/consent solicitation and other relevant materials, and plans to file with the SEC other documents regarding the proposed transaction. Once the registration statement has been declared effective, the final joint proxy statement / prospectus / consent solicitation will be sent to the stockholders of PharmAthene and Theraclone in connection with the stockholder votes on matters relating to the proposed transaction. The proxy statement/prospectus/consent solicitation contains information about PharmAthene, Theraclone, the proposed transaction, and related matters. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT / PROSPECTUS / CONSENT SOLICITATION (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY AS THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN, AS THE CASE MAY BE, IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER AND RELATED MATTERS. In addition to receiving the proxy statement/prospectus/consent solicitation and proxy card by mail, stockholders will also be able to obtain the proxy statement/prospectus/consent solicitation, as well as other filings containing information about PharmAthene, without charge, from the SEC's website ( http://www.sec.gov) or, without charge, by contacting Stacey Jurchison at PharmAthene at (410) 269-2610. No Offer or Solicitation
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts